Printer Friendly

ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991

ENDOTRONICS, INC. REPORTS RESULTS FOR FIRST QUARTER ENDED DEC. 31, 1991
 MINNEAPOLIS, Feb. 18 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) today announced operating results for the quarter ended Dec. 31, 1991. The company reported increased revenues for the first quarter of fiscal 1992 of $933,041 compared to $724,296 for the same period in fiscal 1991. The company reported a decrease in net loss to $424,288, or ($0.02 per share) for the first quarter compared to $664,006, or ($0.04 per share) for the same period last year.
 Also during the quarter, the company signed a cooperative agreement with the University of Minnesota to develop a bio-artificial liver (BAL) device. Additionally, Endotronics introduced its new ACUMOUSE(TM) cell culture system, designed to replace laboratory mice as a source of monoclonal antibodies.
 Richard E. Sakowicz, president and chief operating officer of Endotronics, Inc., commented, "Historically the first quarter has been a slow quarter for sales for Endotronics due to the holiday season and the fact that it coincides with the year-end budgeting process for many of our customers. This year, however, first-quarter revenues benefited from increased sales of instruments and disposables, as well as an increase in grant revenue that resulted from a five-year National Institutes of Health grant awarded in September 1990. We continue to implement our growth plan emphasizing expansion into the bioprocessing market and leveraging our cell culture technology and biomedical engineering capabilities into the human health care market."
 ENDOTRONICS, INC.
 CONDENSED STATEMENTS OF OPERATIONS
 (In thousands, excepts per-share amounts)
 Three Months Ended Dec. 31,
 (Unaudited)
 1991 1990
 Revenues $933 $724
 Operating loss $(378) $(590)
 Net loss $(424) $(664)
 Net loss per common share $(0.02) $(0.04)
 Weighted average number of
 common shares outstanding 18,652 16,596
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized leader in hollow fiber cell culture instrumentation with more than 675 instruments installed worldwide.
 -0- 2/18/92
 /CONTACT: Yvonne L. Marschner-Bova of Endotronics, 313-871-7350/
 (ENDO) CO: Endotronics, Inc. ST: Minnesota IN: MTC SU: ERN :END KK-SB -- DE013 -- 9865 02/18/92 11:06 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 18, 1992
Words:370
Previous Article:OMNICORP AGREES TO ACQUIRE INDUSTRIAL MAINTENANCE AND ENVIRONMENTAL CLEANING SERVICES COMPANIES
Next Article:SEVENSON ENVIRONMENTAL SERVICES, INC., REPORTS EARNINGS FOR THE QUARTER AND YEAR ENDED DEC. 31, 1991
Topics:


Related Articles
ENDOTRONICS, INC. INTRODUCES ACUMOUSE CELL CULTURE INSTRUMENT -- COST-EFFECTIVE SUBSTITUTE FOR LABORATORY MICE
ENDOTRONICS, INC. REPORTS FOURTH-QUARTER PROFIT, LOSS FOR YEAR
UNIVERSITY OF MINNESOTA AND ENDOTRONICS, INC. TO COLLABORATE ON DEVELOPMENT OF BIO-ARTIFICIAL DEVICE TO REPLACE LIVER FUNCTION
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
ADVANCED MAGNETICS, INC. REPORTS FISCAL 1992 FIRST QUARTER RESULTS
ONCOGENE SCIENCE REPORTS FIRST QUARTER RESULTS
CALGENE ANNOUNCES FIRST HALF RESULTS
ENDOTRONICS, INC. RECEIVES $1 MILLION PURSUANT TO INVESTMENT AGREEMENT WITH INTEGRA HOLDING AG OF SWITZERLAND
INTERFERON SCIENCES REPORTS 1991 OPERATING RESULTS
ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters